Diagenode

LGC will supply DNA fragmentation instruments for clinical and agricultural biotechnology customers.

The Belgian company recently received €3.6 million to develop the signature into a clinical test within the next three years.

NEW YORK (GenomeWeb) — Becton Dickinson's BD Diagnostics division announced this week the launch of the Total Nucleic Acid suite, a kit of reagents to enable DNA- and RNA-based assay development on the automated BD Max platform.

The US Food and Drug Administration has approved BioFire Diagnostics' FilmArray Blood Culture Identification Panel. BioFire said that the 27-target panel is the most comprehensive blood culture test to be approved by the FDA.

Luminex said this week that it has received clearance from the US Food and Drug Administration for its MagPix instrument and xTAG Gastrointestinal Pathogen Panel, or GPP.

BD Diagnostics, a division of Becton Dickinson, and Belgium's Diagenode this week announced the European launch of Diagenode's influenza A and B assay for use on the BD Max molecular testing system.

NEW YORK (GenomeWeb News) – Rubicon Genomics will integrate its ThruPlex technology into Diagenode's epigenetics platforms under a partnership announced today.

BGI and Diagenode will collaborate to develop standard methods in sample prep for next-generation sequencing for epigenetics research, the companies said today.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – BGI and Diagenode are collaborating to implement standard methods in epigenetics and next-generation sequencing sample preparation.

Pages

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.

NPR reports that government and private insurers are being slow to cover recently approved CAR-T cell therapies.

CNBC reports that there are thousands of genetic tests available for consumers to chose between.

In Nature this week: genomic analysis of ducks, whole-genome doubling among tumor samples, and more.